DERM
Journey Medical Corp
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Journey Medical has 5 disclosed suppliers and 2 disclosed customers in SEC filings.
Last report0 of 4 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+3.42%
vs ±84.3% implied · ×0.04
shaded = implied · ▲▼ = realized
SentenceOn March 31, 2021, we executed an asset purchase agreement for Qbrexza (the "Qbrexza APA") with Dermira Inc. ("Dermira"), pursuant to which we acquired global ownership to Qbrexza (glycopyrronium), a prescription cloth towelette approved to treat primary axillary hyperhidrosis in people nine years of age and older.
DERM 10-Kaccession 0001104659-26-034629
SentenceOn May 21, 2025, we entered into a Manufacturing and Supply Agreement for Targadox (the "Targadox Agreement") with Epic Pharma, LLC ("Epic").
DERM 10-Kaccession 0001104659-26-034629
SentenceAs part of the Qbrexza APA, we were assigned an exclusive license agreement with Rose University ("Rose U") pursuant to which we obtained a worldwide exclusive license within a field of use including hyperhidrosis to practice, enforce and otherwise exploit certain patent rights, know-how and data related to Qbrexza.
DERM 10-Kaccession 0001104659-26-034629
SentenceOn December 18, 2020, we entered into an asset purchase agreement for our Anti-itch Product (the "Anti-itch APA") with Sun Pharmaceutical Industries, Inc. ("Sun").
DERM 10-Kaccession 0001104659-26-034629
SentenceOn January 12, 2022, we entered into an Asset Purchase Agreement (the "Vyne APA") with Vyne Therapeutics Inc. ("Vyne") to acquire Vyne's Molecule Stabilizing Technology™ franchise (the "Acquisition") for an upfront payment of $20.0 million, with an additional $5.0 million payment due on the one-year anniversary of the closing of the Acquisition.
DERM 10-Kaccession 0001104659-26-034629
SentenceOther revenue for the year ended December 31, 2025, reflects the supply to Cutia of Amzeeq for commercial use and sales-based royalties on Cutia's net sales of Amzeeq, pursuant to the Cutia Agreement.
DERM 10-Kaccession 0001104659-26-034629
SentenceOn August 31, 2023, we entered into the New License Agreement with Maruho Co. Lts. ("Maruho"), whereby we granted an exclusive license to Maruho to develop and commercialize Qbrexza for the treatment of primary axillary hyperhidrosis in South Korea, Taiwan, Hong Kong, Macau, Thailand, Indonesia, Malaysia, Philippines, Singapore, Vietnam, Brunei, Cambodia, Myanmar and Laos.
DERM 10-Kaccession 0001104659-26-034629
Largest filed tie
—
Journey Medical Corp
5.19
Expected move
Inputsspot 5.17exp Nov 20ATM strike 5ATM straddle 4.93IV 542%